Special NoticeNAICS 32541211d

6505--Notice of Intent to Sole-Source for Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) and Lutathera (Lutetium Lu 177 Dotatate) for Buffalo VA Medical Center

36C24227Q0031

VETERANS AFFAIRS, DEPARTMENT OF → VETERANS AFFAIRS, DEPARTMENT OF.VETERANS AFFAIRS, DEPARTMENT OF.242-NETWORK CONTRACT OFFICE 02 (36C242) → 242-NETWORK CONTRACT OFFICE 02 (36C242)

Posted: Oct 2, 2026
Deadline: Oct 15, 2026 · 4:00 PM EDT
Est. Value: Not specified
Location: N/A

AI Summary

The Buffalo VA Medical Center intends to sole-source the purchase of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) and Lutathera (Lutetium Lu 177 Dotatate), two radiopharmaceutical drugs used in cancer treatment. This is a Special Notice of intent to sole-source, with responses due by October 15, 2026. Only the manufacturer or authorized distributors of these specific radiopharmaceuticals would be viable bidders, and this notice primarily signals the government's intent rather than an open competition.

Key Requirements

•Must be an authorized source for the proprietary radiopharmaceuticals Pluvicto and Lutathera, with appropriate radioactive materials licensing for handling and delivering Lutetium Lu 177 therapies.

Details

Point of Contact: Myra Florisa N. Green; Myra.Green2@va.gov; 518-626-5086
Required Certifications: NRC radioactive materials license, State radioactive materials license, FDA approval as manufacturer or authorized distributor, SAM.gov registration
Classification Code: 6505

View on SAM.gov

OCCASIONAL

242-NETWORK CONTRACT OFFICE 02 (36C242) posted 1 similar opportunity in 60 days. Last: Sep 2, 2026.

Unlock More Intelligence

Fit Score

See how well this opportunity matches your company's capabilities, NAICS codes, and set-asides.

Incumbent Intelligence

Know who holds the current contract, their award amounts, and contract history.

Proposal Help

AI-generated proposal outlines, compliance checklists, and win-theme suggestions.

Get Started →

GovWin charges $15,000/year. We start at $49/month.